Group RPH and OncoBeta GmbH sign agreement for Sales Referral and Distribution of Rhenium-SCT® in Brazil.

Porto Alegre, Brazil and Garching n. Munich, Germany– OncoBeta® GmbH, a commercial stage Medical Device Company specialized in innovative epidermal radioisotope therapies for Non-Melanocytic Skin Cancers (NMSCs), is pleased to announce today that it has entered an exclusive Sales Referral and Distribution agreement with Grupo RPH to start Rhenium-SCT® (Skin Cancer Therapy) treatments in Brazil.

As a leading brand in the Brazilian nuclear medicine market and one of the biggest of the sector in Latin America, Grupo RPH will employ its extensive knowledge on this area to introduce, distribute and service the Rhenium-SCT® therapy in Brazil. Under this agreement, Grupo RPH and OncoBeta® GmbH will work together sharing one mission: to promote the quality of life to patients with non-melanoma skin cancer.

The global incidence of non-melanoma skin cancers has been drastically increasing over the past decades. Depending on the source, it is estimated that there are over 5 million non-melanoma skin cancer cases reported globally each year. NMSC is one of the most common forms of cancer in Brazil. Presently the number of newly diagnosed cases in Brazil is approximately 200,000 annually. It is expected that this number will increase dramatically over the next few years.

Grupo RPH Managing Director, Rafael Madke stated, “Grupo RPH is very glad to establish the partnership with OncoBeta® GmbH. The Rhenium-SCT® is a ground-breaking technology that will change the therapeutic practice of non-melanoma skin cancer. This agreement sets the start of a long-term partnership between Grupo RPH and OncoBeta® GmbH to bring other innovative technologies to Brazil”

“This partnership and cooperation brings a fantastic opportunity to patients suffering from skin cancer in Brazil who will soon be able to be treated with the Rhenium-SCT® .” states Shannon D. Brown III, CEO and Managing Director of OncoBeta® GmbH. “We are very excited to be able to join forces with a leader in the nuclear medicine market in Latin America such as Grupo RPH which is a further step in making the Rhenium-SCT® more accessible to patients worldwide”.

About the Rhenium-SCT® (Skin Cancer Therapy)

The Rhenium-SCT® is a non-invasive, painless therapy generally providing for unparalleled aesthetic results, even in cases otherwise considered difficult to treat. The Rhenium-SCT® utilizes the radioisotope Rhenium-188 in an epidermal application with optimal properties for the treatment of NMSCs (non-melanoma skin cancers). Due to the specially designed devices and accessories the Rhenium-SCT® compound never comes in direct contact with the patients’ skin and the application is safe and simple for the applying physician. Most cases of non-melanoma skin cancers (Basal Cell Carcinomas and Squamous Cell Carcinomas) can be treated using the Rhenium-SCT® with a single application, applied in one single session. Scar-free healing of the treated lesion area and the regeneration of healthy tissue occurs usually within a few weeks after treatment.

About Grupo RPH

Operating since 2004, Grupo RPH commercially delivers eight different Cold Kits for Tc99m and Ga68 preparation for the Brazilian market. Grupo RPH is also the proud owner of the only private-owned fully GMP production facility in Brazil for nuclear medicine products. Grupo RPH’s products are sold throughout the whole Brazilian territory, serving nearly 400 customers on a daily basis. Grupo RPH is also a pioneer of the Centralized Radiopharmacy model in Brazil.

For more information visit http://gruporph.com.br/en/